Ionis Pharma's olezarsen has become the first FDA-approved drug therapy for adults with familial chylomicronaemia syndrome (FCS), an ultra-rare disease that leads to elevated triglyceride levels ...

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).

Rob Manfred announces ABS coming to the MLB in 2026, Jerry Reinsdorf lays out his plan for the next owner of the Chicago White Sox and the guys roll out another Friday edition of The Good, The Bad ...